This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Sep 2015

Novo Nordisk to build manufacturing facility in Iran

The plant will manufacture FlexPen prefilled devices.

Novo Nordisk has that Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding committing Novo Nordisk to build a local manufacturing plant for FlexPen prefilled devices in Iran.

The project is expected to last 5 years and represents a Novo Nordisk investment of approximately 70 million euros. The production will function in compliance with GMP, which will ensure the quality and reliability of the products.

"We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to 5 million people have diabetes according to the International Diabetes Federation. This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products," said Ole Moelskov Bech, corporate vice president of Novo Nordisk Business Area Near East.

With construction of the new facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs around 130 people in Iran.

Related News